Registry for metastatic breast cancer in Austria

Metastatic Breast Cancer in Austria

Observational Arbeitsgemeinschaft medikamentoese Tumortherapie · NCT03870620

This study is collecting information from people with metastatic breast cancer in Austria to better understand the disease and how different treatments are working.

Quick facts

Study typeObservational
Enrollment5000 (estimated)
Ages18 Years and up
SexAll
SponsorArbeitsgemeinschaft medikamentoese Tumortherapie Academic / other
Locations16 sites (Salzburg, State of Salzburg and 15 other locations)
Trial IDNCT03870620 on ClinicalTrials.gov

What this trial studies

This registry collects and documents data on patients with metastatic breast cancer in Austria, aiming to provide a comprehensive overview of the disease's characteristics and treatment outcomes. It includes both prospective and retrospective data collection, focusing on tumor characteristics, medical histories, and treatment sequences. The registry will analyze factors such as median age at metastasis, disease-free survival, and the distribution of metastatic subtypes, ultimately contributing to a better understanding of the disease in the Austrian population.

Who should consider this trial

Good fit: Ideal candidates for this registry are patients with histologically confirmed breast cancer and evidence of metastases within the last 10 years.

Not a fit: Patients with non-histological evidence of breast cancer or those without metastases will not benefit from this registry.

Why it matters

Potential benefit: If successful, this registry could enhance the understanding of metastatic breast cancer and improve treatment strategies for patients.

How similar studies have performed: While this registry approach is systematic, similar studies have shown success in documenting cancer characteristics and improving treatment outcomes.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Histological evidence of breast cancer
* Histological and/or radiological evidence of metastases
* Metastasis within 10 years of registry initiation
* Signed informed consent (if a patient has already died at the time of entry, the entry can be made without a declaration of consent)

Exclusion Criteria:

* Due to the non-interventional design of the registry there are no specific exclusion criteria.

Where this trial is running

Salzburg, State of Salzburg and 15 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Breast CancerBreast CarcinomaBreast Tumor
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.